These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 23016588)

  • 21. Type I interferon subtypes produced by human peripheral mononuclear cells from one normal donor stimulated by viral and non-viral inducing factors.
    Palmer P; Tovey MG; Raschilas F; Brassart L; Meritet JF; Porcher R; Lebon P
    Eur Cytokine Netw; 2007 Jun; 18(2):108-14. PubMed ID: 17594944
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of residues of the IFNAR1 chain of the type I human interferon receptor critical for ligand binding and biological activity.
    Cajean-Feroldi C; Nosal F; Nardeux PC; Gallet X; Guymarho J; Baychelier F; Sempé P; Tovey MG; Escary JL; Eid P
    Biochemistry; 2004 Oct; 43(39):12498-512. PubMed ID: 15449939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses.
    Buckwold VE; Wei J; Huang Z; Huang C; Nalca A; Wells J; Russell J; Collins B; Ptak R; Lang W; Scribner C; Blanchett D; Alessi T; Langecker P
    Antiviral Res; 2007 Feb; 73(2):118-25. PubMed ID: 16987555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contributions of cloned type I interferon receptor subunits to differential ligand binding.
    Cutrone EC; Langer JA
    FEBS Lett; 1997 Mar; 404(2-3):197-202. PubMed ID: 9119063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanisms of type I interferon signaling in normal and malignant cells.
    Li Y; Srivastava KK; Platanias LC
    Arch Immunol Ther Exp (Warsz); 2004; 52(3):156-63. PubMed ID: 15247882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use.
    Ferrantini M; Capone I; Belardelli F
    Biochimie; 2007; 89(6-7):884-93. PubMed ID: 17532550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Direct effects of type I interferons on cells of the immune system.
    Hervas-Stubbs S; Perez-Gracia JL; Rouzaut A; Sanmamed MF; Le Bon A; Melero I
    Clin Cancer Res; 2011 May; 17(9):2619-27. PubMed ID: 21372217
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The soluble murine type I interferon receptor Ifnar-2 is present in serum, is independently regulated, and has both agonistic and antagonistic properties.
    Hardy MP; Owczarek CM; Trajanovska S; Liu X; Kola I; Hertzog PJ
    Blood; 2001 Jan; 97(2):473-82. PubMed ID: 11154225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutational and structural analysis of the binding interface between type I interferons and their receptor Ifnar2.
    Piehler J; Schreiber G
    J Mol Biol; 1999 Nov; 294(1):223-37. PubMed ID: 10556041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells.
    Gautier G; Humbert M; Deauvieau F; Scuiller M; Hiscott J; Bates EE; Trinchieri G; Caux C; Garrone P
    J Exp Med; 2005 May; 201(9):1435-46. PubMed ID: 15851485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon.
    Blatt LM; Davis JM; Klein SB; Taylor MW
    J Interferon Cytokine Res; 1996 Jul; 16(7):489-99. PubMed ID: 8836913
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stronger growth-inhibitory effect of interferon (IFN)-beta compared to IFN-alpha is mediated by IFN signaling pathway in hepatocellular carcinoma cells.
    Damdinsuren B; Nagano H; Wada H; Kondo M; Ota H; Nakamura M; Noda T; Natsag J; Yamamoto H; Doki Y; Umeshita K; Dono K; Nakamori S; Sakon M; Monden M
    Int J Oncol; 2007 Jan; 30(1):201-8. PubMed ID: 17143530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The antiviral action of interferon is potentiated by removal of the conserved IRTAM domain of the IFNAR1 chain of the interferon alpha/beta receptor: effects on JAK-STAT activation and receptor down-regulation.
    Basu L; Yang CH; Murti A; Garcia JV; Croze E; Constantinescu SN; Mullersman JE; Pfeffer LM
    Virology; 1998 Mar; 242(1):14-21. PubMed ID: 9501047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Domains of interaction between alpha interferon and its receptor components.
    Uzé G; Di Marco S; Mouchel-Vielh E; Monneron D; Bandu MT; Horisberger MA; Dorques A; Lutfalla G; Mogensen KE
    J Mol Biol; 1994 Oct; 243(2):245-57. PubMed ID: 7932753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro sensitivity of human metapneumovirus to type I interferons.
    Scagnolari C; Trombetti S; Selvaggi C; Carbone T; Monteleone K; Spano L; Di Marco P; Pierangeli A; Maggi F; Riva E; Antonelli G
    Viral Immunol; 2011 Apr; 24(2):159-64. PubMed ID: 21449726
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In Vitro and In Vivo Preclinical Effects of Type I IFNs on Gliomas.
    Galani V; Papadatos SS; Alexiou G; Galani A; Kyritsis AP
    J Interferon Cytokine Res; 2017 Apr; 37(4):139-146. PubMed ID: 28387596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interferons and cell growth control.
    Kalvakolanu DV
    Histol Histopathol; 2000 Apr; 15(2):523-37. PubMed ID: 10809374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lambda interferons come to light: dual function cytokines mediating antiviral immunity and damage control.
    Andreakos E; Zanoni I; Galani IE
    Curr Opin Immunol; 2019 Feb; 56():67-75. PubMed ID: 30399529
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Wherefore interferon?
    Gresser I
    J Leukoc Biol; 1997 May; 61(5):567-74. PubMed ID: 9129205
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potentials of interferon therapy in the treatment of pancreatic cancer.
    Booy S; Hofland L; van Eijck C
    J Interferon Cytokine Res; 2015 May; 35(5):327-39. PubMed ID: 25551196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.